EUS-guided celiac plexus neurolysis for pancreas cancer - Finally established or still under review?

Best Pract Res Clin Gastroenterol. 2022 Sep-Dec:60-61:101809. doi: 10.1016/j.bpg.2022.101809. Epub 2022 Nov 22.

Abstract

Patients with pancreas cancer must deal frequently with intractable and refractory pain. Endoscopic ultrasound guided-celiac plexus neurolysis (EUS-CPN) has been the most studied and used therapeutic technique aimed to destroy the pain fibres that allow the pancreas to communicate with the central nervous system. A neurolytic agent, most commonly ethanol, is optimally spread around the celiac axis in order to reduce pain and mitigate narcotic requirements. This can be performed early to prevent the spiral of pain and medication use, or more historically as salvage therapy. Different techniques to best administer the ethanol for effective EUS-CPN are still being debated. New EUS-guided injection techniques with radiofrequency, radioactive, and/or chemotherapeutic agents need more study.

Keywords: Celiac plexus; Endoscopic ultrasound; Ganglia; Neurolysis; Pain; Pancreas cancer.

Publication types

  • Review

MeSH terms

  • Abdominal Pain / drug therapy
  • Celiac Plexus* / diagnostic imaging
  • Endosonography
  • Ethanol / therapeutic use
  • Humans
  • Pain
  • Pancreatic Neoplasms* / diagnostic imaging
  • Pancreatic Neoplasms* / therapy

Substances

  • Ethanol